Homology Medicines, Inc. announced the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the company’s Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children’s Hospital of Philadelphia. She was also recently named President of the American Society of Gene & Cell Therapy (ASGCT). Dr. Davidson has founded several successful biotechnology companies, including Spark Therapeutics, now a member of the Roche Group, which developed and commercialized the first adeno-associated virus (AAV) vector gene therapy for a genetic disease in the U.S. Prior to her current role, Dr. Davidson held the Roy J. Carver Biomedical Research Chair and was the Vice Chair for Research in the Department of Internal Medicine at the University of Iowa. In addition to co-founding Spark, Dr. Davidson’s important contributions to the biotechnology industry include co-founding Talee Bio (now Spirovant Sciences, Inc.) and serving on multiple scientific advisory boards.